ZYPREXA has been approved (12-4-09) for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder 13 to 17 year olds.
There is a warning concerning weight gain and hyperlipidemia with the suggestion that clinicians might consider other products first before prescribing Zyprexa.
Please note the there is also a recommendation that medication should be a part of a total treatment plan that often includes psychological, educational and social interventions.
Adolescent dosing guidelines are provided: starting dose, 2.5mg or 5mg with a target dose of 10mg. Increments up or down should be made in 2.5mg or 5mg increments. Safety and effectiveness above 20mg once a day has not been established. The dosing guidelines apply to all the diagnoses.
The revised Zyprexa label is located here